Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-U.S. Momentum Factor Index (ASHUMOM)
6/3/2026, 12:00:00 AM
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Korean Translation
2026년 6월 3일, Johnson & Johnson은 니포칼리맙의 2상 JASMINE 연구에서 1차 평가변수를 충족했다고 발표함. 주요 파이프라인의 긍정적인 임상 데이터는 5-10%의 시장 영향을 미칠 것으로 예상됨.
Related Recent Events
Sun Hung Kai Properties Ltd (16) · Earnings Release
Full year results for fiscal year 2026 scheduled.
9/3/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Lam Research Corp (LRCX) · Earnings Release
Lam Research is expected to report its Q4 2026 earnings on July 29, 2026. Analysts forecast an EPS of approximately $1.65-$1.68. Market impact is estimated at Medium as earnings reports typically drive significant price volatility, scheduled.
7/29/2026, 12:00:00 AM
Southern Copper Corporation (SCCO) · Earnings Release
Q2 2026 earnings release is scheduled. Analysts forecast EPS to be around $1.74-$1.85 scheduled.
7/29/2026, 12:00:00 AM
COSCO SHIPPING Energy Transportation Co. Ltd. (1138) · Other
Ex-dividend date for the 2025 final dividend of HKD 0.43007 per share on 2026-07-17; market analysts justify medium impact due to dividend payout; event scheduled.
7/17/2026, 12:00:00 AM
Sinotruk (Hong Kong) Ltd (3808) · Other
Ex-dividend date for the HK$0.88 per share final dividend for the year ended December 31, 2025, is scheduled for July 9, 2026; low importance as a routine technical adjustment is scheduled.
7/9/2026, 12:00:00 AM